Synthego

Biotech

Best-in-class solutions designed for advancing CRISPR therapeutics.

AAF Entry: Series B, June 2017

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. Based on a foundation of engineering and chemistry, Synthego leverages automation and machine learning to synthesize high-quality CRISPR reagents for science at scale. Synthego’s mission is to enable agile life science research and development from discovery through clinical trials by providing scientists with comprehensive CRISPR solutions for each phase coupled with full technical and regulatory support from industry-leading experts. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale.

Synthego has raised $450M to date from the likes of Founders Fund, 8VC, Perceptive Advisors, RA Capital Management & Wellington Management.

AAF Management Ltd.

AAF Management Ltd. (AAF) is a leading early stage venture capital firm focused on Pre-Seed, Seed and Series A stage technology companies in North America.

Washington D.C | Abu Dhabi